Gilead

WHO advises against use of Remdesivir to treat COVID-19, says drug has no 'important effect' to reduce deaths

A WHO Guideline Development Group of international experts said there was 'no evidence based on currently available data that the anti-viral drug does improve patient-important outcomes'

Mylan's remdesivir to cost Rs 4,800 per 100 mg vial in India, 80% cheaper than price tag in wealthy nations

Gilead priced remdesivir at $2,340 per patient for rich nations and agreed to send nearly all of its supply of the drug to the United States over the next three months

Coronavirus Outbreak: Gilead Sciences says supply of Remdesivir to exceed 20 lakh by end of the year

Gilead Sciences Inc expects supply of its potential COVID-19 drug Remdesivir to exceed twenty lakh courses by year-end, the company said on Monday, more than double its previous target of 10 lakh.

Hetero gets DCGI nod to launch anti-viral drug Remdesivir under brand name Covifor for COVID-19 treatment

The drug has been granted approval by DCGI for the treatment of suspected or laboratory-confirmed cases of COVID-19 in adults and children, hospitalised with severe symptoms of the disease, the company said.

FDA warns against the usage of Remdesivir along with malaria antiviral hydroxychloroquine

FDA said it was no longer reasonable to believe that oral formulations of HCQ maybe effective in treating the illness caused by COVID-19.

Gilead's Remdesivir prevented lung disease in macaque monkeys infected with coronavirus: Study

The antiviral drug, Remdesivir is the first drug shown to be effective against COVID-19 in human trials.

Gilead granted marketing authorisation for remdesivir for potential Covid-19 treatment in India

India has allowed adults and children who have been hospitalised with severe COVID-19 symptoms to be treated with Remdesivir

Remdesivir improved symptoms when administered to moderately ill COVID-19 patients: Gilead

The administration of this drug will be given to patients who show signs of a sever COVID-19 infection for a period of five days as well.

Coronavirus India Update, May 14: Cases cross 78,000, Goa no longer a Green Zone, India to test 4 drugs for WHO trials

The total number of COVID-19 cases in India has reached 78,003, with the death toll surging to 2,549. The current number of active cases is 49,219.

Jubilant Life Sciences shares jump 5% after company signs pact with Gilead COVID-19 therapy drug

Shares of Jubilant Life Sciences on Wednesday rose 5 percent after the company said it has entered into a pact with Gilead Sciences for an investigational drug, remdesivir which is a potential therapy for COVID-19